Follow up your unexpected clinical observations!

References

• Dahl O, Borkamo ED, Fluge O. Current status of antivascular therapy and targeted treatment in the clinic. Int J Hyperthermia 2008; 24: 97–110
   PubMed Web of Science ®Google Scholar
• Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74–108
   PubMed Web of Science ®Google Scholar
• Sjodahl K, Jia C, Vatten L, Nilsen T, Hveem K, Lagergren J. Salt and gastric adenocarcinoma: A population-based cohort study in Norway. Cancer Epidemiol Biomarkers Prev 2008; 17: 1997–2001
   PubMedGoogle Scholar
• Sorbye H, Kvinnsland S, Svanes K. Effect of salt-induced mucosal damage and healing on penetration of N-methyl-N'-nitro-N-nitrosoguanidine to proliferative cells in the gastric mucosa of rats. Carcinogenesis 1994; 15: 673–9
   PubMedGoogle Scholar
• Nguyen LT, Uchida T, Murakami K, Fujioka T, Moriyama M. Helicobacter pylori virulence and the diversity of gastric cancer in Asia. J Med Microbiol 2008; 57: 1445–53
   PubMedGoogle Scholar
• Maruyama K, Sasako M, Kinoshita T, Sano T, Katai H, Hada M, et al. Should systematic lymph node dissection be recommended for gastric cancer?. Eur J Cancer 1998; 34: 1480–9
   PubMedGoogle Scholar
• Macdonald JS, Smalley SR, Benedetti J, Hundahl SA, Estes NC, Stemmermann GN, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001; 345: 725–30
   PubMed Web of Science ®Google Scholar
• Lello E, Furnes B, Edna TH. Short and long-term survival from gastric cancer. A population-based study from a county hospital during 25 years. Acta Oncol 2007; 46: 308–15
   PubMed Web of Science ®Google Scholar
• Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006; 355: 11–20
   PubMed Web of Science ®Google Scholar
• Bouche O, Ychou M, Burtin P, Bedenne L, Ducreux M, Lebreton G, et al. Adjuvant chemotherapy with 5-fluorouracil and cisplatin compared with surgery alone for gastric cancer: 7-year results of the FFCD randomized phase III trial (8801). Ann Oncol 2005; 16: 1488–97
   PubMed Web of Science ®Google Scholar
• Cunningham D, Chua YJ. East meets west in the treatment of gastric cancer. N Engl J Med 2007; 357: 1863–5
   PubMed Web of Science ®Google Scholar
• Ragnhammar P, Hafstrom L, Nygren P, Glimelius B. A systematic overview of chemotherapy effects in colorectal cancer. Acta Oncol 2001; 40: 282–308
   PubMed Web of Science ®Google Scholar
• Dupont J, Jensen HA, Jensen BV, Pfeiffer P. Phase I study of short-time oxaliplatin, capecitabine and epirubicin (EXE) as first line therapy in patients with non-resectable gastric cancer. Acta Oncol 2007; 46: 330–5
   PubMed Web of Science ®Google Scholar
• Foukakis T, Lundell L, Gubanski M, Lind PA. Advances in the treatment of patients with gastric adenocarcinoma. Acta Oncol 2007; 46: 277–85
   PubMed Web of Science ®Google Scholar
• Oh SY, Kwon HC, Seo BG, Kim SH, Kim JS, Kim HJ. A phase II study of oxaliplatin with low dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFOX-4) as first line therapy for patients with advanced gastric cancer. Acta Oncol 2007; 46: 336–41
   PubMed Web of Science ®Google Scholar
• Tempero MA, Uchida E, Takasaki H, Burnett DA, Steplewski Z, Pour PM. Relationship of carbohydrate antigen 19-9 and Lewis antigens in pancreatic cancer. Cancer Res 1987; 47: 5501–3
   PubMed Web of Science ®Google Scholar
• Catalano V, Graziano F, Santini D, D'Emidio S, Baldelli AM, Rossi D, et al. Second-line chemotherapy for patients with advanced gastric cancer: Who may benefit?. Br J Cancer 2008; 99: 1402–7
   PubMedGoogle Scholar
• Kim H, Lee K-W, Kim Y, Oh D-Y, Kim J, Im SA, et al. Chemotherapy-induced transient CEA and CA 19-9 surges in patients with metastatic or recurrent gastric cancer. Acta Oncol 2009; 48: 385–90.
   Google Scholar
• Therasse P, Eisenhauer EA, Verweij J. RECIST revisited: A review of validation studies on tumour assessment. Eur J Cancer 2006; 42: 1031–9
   PubMed Web of Science ®Google Scholar
• Aquino A, Formica V, Prete SP, Correale PP, Massara MC, Turriziani M, et al. Drug-induced increase of carcinoembryonic antigen expression in cancer cells. Pharmacol Res 2004; 49: 383–96
   PubMed Web of Science ®Google Scholar
• Prete SP, Turriziani M, Massara MC, De Rossi A, Correale P, De Vecchis L, et al. Combined effects of 5-fluorouracil, folinic acid and oxaliplatin on the expression of carcinoembryonic antigen in human colon cancer cells: Pharmacological basis to develop an active antitumor immunochemotherapy. J Exp Clin Cancer Res 2008; 27: 5
   PubMed Web of Science ®Google Scholar
• Ailawadhi S, Sunga A, Rajput A, Yang GY, Smith J, Fakih M. Chemotherapy-induced carcinoembryonic antigen surge in patients with metastatic colorectal cancer. Oncology 2006; 70: 49–53
   PubMed Web of Science ®Google Scholar
• Moertel CG, Fleming TR, Macdonald JS, Haller DG, Laurie JA. Hepatic toxicity associated with fluorouracil plus levamisole adjuvant therapy. J Clin Oncol 1993; 11: 2386–90
   PubMed Web of Science ®Google Scholar
• Horwich A, Peckham MJ. Transient tumor marker elevation following chemotherapy for germ cell tumors of the testis. Cancer Treat Rep 1986; 70: 1329–31
   PubMedGoogle Scholar
• Vogelzang NJ, Lange PH, Goldman A, Vessela RH, Fraley EE, Kennedy BJ. Acute changes of alpha-fetoprotein and human chorionic gonadotropin during induction chemotherapy of germ cell tumors. Cancer Res 1982; 42: 4855–61
   PubMed Web of Science ®Google Scholar
• Kiang DT, Greenberg LJ, Kennedy BJ. Tumor marker kinetics in the monitoring of breast cancer. Cancer 1990; 65: 193–9
   PubMedGoogle Scholar
• Loprinzi CL, Tormey DC, Rasmussen P, Falkson G, Davis TE, Falkson HC, et al. Prospective evaluation of carcinoembryonic antigen levels and alternating chemotherapeutic regimens in metastatic breast cancer. J Clin Oncol 1986; 4: 46–56
   PubMedGoogle Scholar
• Mughal AW, Hortobagyi GN, Fritsche HA, Buzdar AU, Yap HY, Blumenschein GR. Serial plasma carcinoembryonic antigen measurements during treatment of metastatic breast cancer. JAMA 1983; 249: 1881–6
   PubMed Web of Science ®Google Scholar
• Sonoo H, Kurebayashi J. Serum tumor marker kinetics and the clinical course of patients with advanced breast cancer. Surg Today 1996; 26: 250–7
   PubMedGoogle Scholar
• Sorbye H, Dahl O. Nordic 5-fluorouracil/leucovorin bolus schedule combined with oxaliplatin (Nordic FLOX) as first-line treatment of metastatic colorectal cancer. Acta Oncol 2003; 42: 827–31
   PubMed Web of Science ®Google Scholar
• Sorbye H, Glimelius B, Berglund A, Fokstuen T, Tveit KM, Braendengen M, et al. Multicenter phase II study of Nordic fluorouracil and folinic acid bolus schedule combined with oxaliplatin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 2004; 22: 31–8
   PubMedGoogle Scholar
• Sorbye H, Dahl O. Carcinoembryonic antigen surge in metastatic colorectal cancer patients responding to oxaliplatin combination chemotherapy: Implications for tumor marker monitoring and guidelines. J Clin Oncol 2003; 21: 4466–7
   PubMed Web of Science ®Google Scholar
• Sorbye H, Dahl O. Transient CEA increase at start of oxaliplatin combination therapy for metastatic colorectal cancer. Acta Oncol 2004; 43: 495–8
   PubMed Web of Science ®Google Scholar
• Locker GY, Hamilton S, Harris J, Jessup JM, Kemeny N, Macdonald JS, et al. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol ;24 2006; 24: 5313–27
   PubMed Web of Science ®Google Scholar
• Iwanicki-Caron I, Di Fiore F, Roque I, Astruc E, Stetiu M, Duclos A, et al. Usefulness of the serum carcinoembryonic antigen kinetic for chemotherapy monitoring in patients with unresectable metastasis of colorectal cancer. J Clin Oncol 2008; 26: 3681–6
   PubMed Web of Science ®Google Scholar
• Fakih MG. Carcinoembryonic antigen monitoring in metastatic colorectal cancer: Words of caution. J Clin Oncol 2008; 26: e7
   PubMedGoogle Scholar